T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.45B |
| 2 |
Pinterest
PINS
|
+$1.89B |
| 3 |
T-Mobile US
TMUS
|
+$1.89B |
| 4 |
Zoom
ZM
|
+$1.77B |
| 5 |
UiPath
PATH
|
+$1.71B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$3.66B |
| 2 |
Caterpillar
CAT
|
+$1.32B |
| 3 |
Netflix
NFLX
|
+$1.18B |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$1.15B |
| 5 |
Micron Technology
MU
|
+$1.07B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.62% |
| 2 | Healthcare | 16.07% |
| 3 | Consumer Discretionary | 15.29% |
| 4 | Communication Services | 13.46% |
| 5 | Financials | 12.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ATNX
2726
DELISTED
Athenex, Inc. Common Stock
ATNX
| $196K | ﹤0.01% |
+2,125
| New | +$193K |
|
|
PFBI
2727
DELISTED
Premier Financial Bancorp
PFBI
| $193K | ﹤0.01% |
11,464
+299
| +3% | +$5.54K |
|
2728
LifeVantage
LFVN
$80.4M
| $190K | ﹤0.01% |
25,900
-1,068
| -4% | -$8.72K |
|
|
ADVM
2729
DELISTED
Adverum Biotechnologies
ADVM
| $189K | ﹤0.01% |
5,410
-52,483
| -91% | -$2.83M |
|
2730
Organogenesis Holdings
ORGO
$229M
| $189K | ﹤0.01% |
+11,364
| New | +$212K |
|
|
BHR
2731
Braemar Hotels & Resorts
BHR
$140M
| $188K | ﹤0.01% |
30,233
+3,915
| +15% | +$24.1K |
|
|
CHMI
2732
Cherry Hill Mortgage Investment Corp
CHMI
$108M
| $188K | ﹤0.01% |
19,030
-1,106
| -5% | -$11K |
|
2733
Primis Financial Corp
FRST
$417M
| $186K | ﹤0.01% |
12,180
+614
| +5% | +$9.21K |
|
2734
Immunovant
IMVT
$8.65B
| $186K | ﹤0.01% |
17,603
+345
| +2% | +$4.82K |
|
|
HGEN
2735
DELISTED
HUMANIGEN, INC.
HGEN
| $186K | ﹤0.01% |
+10,721
| New | +$195K |
|
2736
Aqua Metals
AQMS
$9.67M
| $185K | ﹤0.01% |
309
+83
| +37% | +$50.6K |
|
2737
Golub Capital BDC
GBDC
$3.45B
| $185K | ﹤0.01% |
12,000
-1,000
| -8% | -$15.5K |
|
2738
Kiniksa Pharmaceuticals
KNSA
$6.09B
| $184K | ﹤0.01% |
+13,231
| New | +$201K |
|
2739
Mammoth Energy Services
TUSK
$157M
| $183K | ﹤0.01% |
39,800
-4,470
| -10% | -$18.4K |
|
|
CLSD
2740
DELISTED
Clearside Biomedical
CLSD
| $181K | ﹤0.01% |
2,480
-827
| -25% | -$38.4K |
|
|
STEX
2741
Streamex Corp
STEX
$89.1M
| $180K | ﹤0.01% |
4,660
-169
| -3% | -$6.31K |
|
2742
Intellicheck
IDN
$73.7M
| $179K | ﹤0.01% |
21,400
+4,485
| +27% | +$36.8K |
|
|
RJET
2743
Republic Airways Holdings
RJET
$960M
| $179K | ﹤0.01% |
1,283
-195
| -13% | -$31.4K |
|
2744
VistaGen Therapeutics
VTGN
$11.6M
| $179K | ﹤0.01% |
1,892
+575
| +44% | +$42.6K |
|
|
ADMS
2745
DELISTED
Adamas Pharmaceuticals
ADMS
| $178K | ﹤0.01% |
33,700
-30,000
| -47% | -$155K |
|
|
SHSP
2746
DELISTED
SharpSpring, Inc.
SHSP
| $176K | ﹤0.01% |
10,400
| – | – |
|
2747
Akebia Therapeutics
AKBA
$248M
| $174K | ﹤0.01% |
46,023
+3,349
| +8% | +$11.3K |
|
|
SELF
2748
Global Self Storage
SELF
$59.4M
| $174K | ﹤0.01% |
33,399
+2,000
| +6% | +$10.7K |
|
2749
Stereotaxis
STXS
$138M
| $173K | ﹤0.01% |
17,955
+1,506
| +9% | +$11.9K |
|
2750
SELLAS Life Sciences
SLS
$2.4B
| $172K | ﹤0.01% |
15,500
-11,600
| -43% | -$113K |
|
Similar funds
T. Rowe Price Associates's Q2 2021 Portfolio in Review
As of Q2 2021, T. Rowe Price Associates held 3,000 positions worth $1.08T, up 8% from $999B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2021 filing shows 159 new, 1,164 increased, 1,499 reduced and 84 closed positions. Its largest new stake was UiPath: 23,377,090 shares worth $1.52B. The largest sale was Alibaba, an estimated $3.66B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2021 buy was UiPath: 23,377,090 shares worth $1.52B.
- T. Rowe Price Associates added most to Microsoft in Q2 2021, an estimated $3.45B increase.
- T. Rowe Price Associates's biggest Q2 2021 reduction was Alibaba, cutting an estimated $3.66B.
- T. Rowe Price Associates fully exited Pershing Square Tontine Holdings, Ltd. in Q2 2021, selling an estimated $145M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.08T portfolio in Q2 2021.
- T. Rowe Price Associates opened 159 new positions and closed 84 in Q2 2021.
- T. Rowe Price Associates's portfolio value rose 8% quarter-over-quarter to $1.08T.
Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.